TransDigm reported a 14% year-over-year increase in sales, reaching $2.29 billion in Q1 of fiscal 2026, and delivered adjusted EPS of $8.23, up 5% from $7.83 a year ago and 2.6% above the Zacks Consensus Estimate of $8.02. GAAP EPS was $6.62, down from $7.62 in the prior-year period, reflecting higher interest expenses. Organic sales growth of 7.4% supported a 9.3% rise in gross profit, and management raised full-year net sales guidance to a range between $9.845 billion and $10.035 billion, while also increasing its adjusted EPS outlook. The company has beaten consensus EPS estimates in three of the last four quarters, underscoring its operational resilience.

BMO Capital reaffirmed its “Outperform” rating on TransDigm, citing confidence in ongoing margin expansion and free cash flow generation. Wall Street analysts have collectively raised earnings estimates for the next two quarters, resulting in a strong upward revision trend. On the charts, TDG has fallen 8.7% over the past four weeks and now registers in oversold territory on relative strength indicators, suggesting that selling pressure may have peaked and setting the stage for a potential technical turnaround.